SMi Group: Hear from Boehringer Ingelheim, Novaliq, Santen, Shire, Aerie Pharmaceuticals at Europe's Leading Ophthalmic Conference
SMi’s Presents Europe's Leading Ophthalmic Conference; Ophthalmic Drugs
London, United Kingdom, September 28, 2017 --(PR.com)-- Here's a quick update on the key industry experts to network with and about their topics. www.ophthalmicdrugs.com/prc
- Dr. Naj Sharif is the Executive Director in R&D, Head, Global Alliances & External Research, at Santen Inc. He has been in the pharmaceutical industry for over 30 years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently now at Santen Inc.
Dr. Sharif will be chairing day 1 of the conference and will also be speaking about invasive glaucoma surgery for various glaucoma treatments, and will address the use of conjugate drugs and a new prostaglandin drug product co-developed by Santen, called 'Omidenepag Isopropyl.'
- Bernhard Guenther is the Co-Founder and Chief Innovation Officer, at Novaliq. Before taking over the CIO position at the end of last year, he served for 12 years as the CEO of the company.
During Bernhard's talk, he will introduce Novaliq’s innovative EyeSol® drug delivery technology, which is based on novel and exclusive water-free excipients which has been established and validated for innovative ophthalmic products.
Attendees will learn about new ideas in developing water-free ocular drugs, the limitations of water-based therapeutics and their broad development program which has already resulting in one product launch.
- Amir Shojaei is the Vice President Therapeutic Area Head, Ophthalmology, at Shire. As the lead for global development and product strategy in R&D for the Ophthalmics franchise at Shire, Amir leads all aspects of clinical stage assets. Most recently, his team brought Xiidra (lifitegrast) from Phase 3 development through to U.S. FDA filing and eventual approval. Amir has owned and run his own pharmaceutical consulting company, is an author on numerous publications in peer-reviewed journals, and is named on several US and international patents.
Amir's talk will discuss the novel approaches to the treatment of ocular diseases, based on the development of lifitegrast, and clinical results from short and long-term safety studies. Attendees can benefit and be inspired, as Amir will also provide rationale behind the development of lifitegrast.
- Victor Chong is the Global Head of Ophthalmology, at Boehringer Ingelheim. Victor Chong is a retinal specialist specialising in macular diseases. He was ophthalmic trained in Moorfields Eye Hospital London, and Retinal Fellowship trained in Moorfields Eye Hospital, London, and Centre of Macular Degeneration, Iowa City, USA. He founded the Laser and Retinal Research Unit at King’s College Hospital, London, before moving to Oxford Eye Hospital, and became the Head of Department in 2010.
During Victor's presentation, he will explore non-invasive therapies for diabetic macular oedema and non- proliferative diabetic retinopathy. The solutions for these diseases will be examined, including light and laser therapy and oral therapies as well as the use of steroids.
Further information is available at: www.ophthalmicdrugs.com/prc
For those looking to attend there is currently a £200 early-bird saving by this Friday 29th September.
SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/prc
Sponsored by: Leica Microsystems | Experimentica
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
- Dr. Naj Sharif is the Executive Director in R&D, Head, Global Alliances & External Research, at Santen Inc. He has been in the pharmaceutical industry for over 30 years holding leadership positions of increasing scope and responsibility, spanning Discovery Research, Drug Development and Regulatory Affairs. He has worked at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently now at Santen Inc.
Dr. Sharif will be chairing day 1 of the conference and will also be speaking about invasive glaucoma surgery for various glaucoma treatments, and will address the use of conjugate drugs and a new prostaglandin drug product co-developed by Santen, called 'Omidenepag Isopropyl.'
- Bernhard Guenther is the Co-Founder and Chief Innovation Officer, at Novaliq. Before taking over the CIO position at the end of last year, he served for 12 years as the CEO of the company.
During Bernhard's talk, he will introduce Novaliq’s innovative EyeSol® drug delivery technology, which is based on novel and exclusive water-free excipients which has been established and validated for innovative ophthalmic products.
Attendees will learn about new ideas in developing water-free ocular drugs, the limitations of water-based therapeutics and their broad development program which has already resulting in one product launch.
- Amir Shojaei is the Vice President Therapeutic Area Head, Ophthalmology, at Shire. As the lead for global development and product strategy in R&D for the Ophthalmics franchise at Shire, Amir leads all aspects of clinical stage assets. Most recently, his team brought Xiidra (lifitegrast) from Phase 3 development through to U.S. FDA filing and eventual approval. Amir has owned and run his own pharmaceutical consulting company, is an author on numerous publications in peer-reviewed journals, and is named on several US and international patents.
Amir's talk will discuss the novel approaches to the treatment of ocular diseases, based on the development of lifitegrast, and clinical results from short and long-term safety studies. Attendees can benefit and be inspired, as Amir will also provide rationale behind the development of lifitegrast.
- Victor Chong is the Global Head of Ophthalmology, at Boehringer Ingelheim. Victor Chong is a retinal specialist specialising in macular diseases. He was ophthalmic trained in Moorfields Eye Hospital London, and Retinal Fellowship trained in Moorfields Eye Hospital, London, and Centre of Macular Degeneration, Iowa City, USA. He founded the Laser and Retinal Research Unit at King’s College Hospital, London, before moving to Oxford Eye Hospital, and became the Head of Department in 2010.
During Victor's presentation, he will explore non-invasive therapies for diabetic macular oedema and non- proliferative diabetic retinopathy. The solutions for these diseases will be examined, including light and laser therapy and oral therapies as well as the use of steroids.
Further information is available at: www.ophthalmicdrugs.com/prc
For those looking to attend there is currently a £200 early-bird saving by this Friday 29th September.
SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/prc
Sponsored by: Leica Microsystems | Experimentica
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Pav Solanki
+44 (0) 20 7827 6048
www.ophthalmicdrugs.com/prc
Pav Solanki
+44 (0) 20 7827 6048
www.ophthalmicdrugs.com/prc
Contact
Categories